Peripheral PD-1⁺ T Cells Co-expressing Inhibitory Receptors Predict SVR with Ultra Short Duration DAA Therapy in HCV Infection

Keyphrases

• T Cells 100%
• Inhibitory Receptors 100%
• Sustained Virological Response 100%
• Programmed Death-ligand 1 (PD-L1) 100%
• Direct-acting Antiviral Therapy 100%
• HCV Infection 100%
• CD8+ T Cells 50%
• End of Therapy 30%
• CD160 30%
• Virus-specific 20%
• Viral Clearance 20%
• Degranulation 20%
• Direct-acting Antivirals 20%
• HCV Patients 20%
• CD8+ 10%
• Genotype 10%
• CD4+ T Cells 10%
• Cytotoxic Activity 10%
• C-statistic 10%
• Receiver Operating Characteristic Curve 10%
• Response Group 10%
• Infected Individual 10%
• Cytokine Expression 10%
• In Vitro Production 10%
• Functional Capacity 10%
• Antiviral Immunity 10%
• CD4+ T Lymphocytes 10%
• Immune Parameters 10%
• Blimp-1 10%
• Specific Immunity 10%
• CD8+ T Cell Subsets 10%
• CD107a 10%
• Therapy Time 10%
• Ultrashort 10%
• Tim-3 10%
• Chronic HCV 10%
• Direct-acting Antiviral Regimens 10%
• HCV Clearance 10%

Medicine and Dentistry

• Antiviral Therapy 100%
• Infection 100%
• Receptor 100%
• T Cell 100%
• Cytotoxic T-Cell 100%
• Antivirus Agent 50%
• Cytokine 33%
• Viral Clearance 33%
• Degranulation 33%
• Virus 33%
• Biological Marker 16%
• Tumor Necrosis Factor 16%
• CD8 Antigen 16%
• T-Helper Cell 16%
• Immunocompetent Cell 16%
• Ex Vivo 16%
• Adaptive Immunity 16%
• Treatment Duration 16%
• Functional Status 16%
• Antiviral Immunity 16%
• T Cell Subset 16%
• CD4+ T Lymphocyte 16%

Immunology and Microbiology

• T Cell 100%
• Cytotoxic T-Cell 100%
• Infection 100%
• CD160 50%
• Cytokine 33%
• Viral Clearance 33%
• Degranulation 33%
• Virus 33%
• CD8 16%
• T-Helper Cell 16%
• Tumor Necrosis Factor 16%
• Immunocompetent Cell 16%
• Adaptive Immune System 16%
• CD4+ T Lymphocyte 16%
• Functional Status 16%
• T Cell Subset 16%
• Antiviral Immunity 16%
• Peptides 16%